Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis.

Kevans D, Murthy S, Mould DR, Silverberg MS.

J Crohns Colitis. 2018 Apr 6. doi: 10.1093/ecco-jcc/jjy028. [Epub ahead of print]

PMID:
29659758
2.

Protocol for a multicentred randomised controlled trial investigating the use of personalised golimumab dosing tailored to inflammatory load in ulcerative colitis: the GOAL-ARC study (GLM dose Optimisation to Adequate Levels to Achieve Response in Colitis) led by the INITIAtive group (NCT 0268772).

Sheridan J, Coe CA, Doran P, Egan L, Cullen G, Kevans D, Leyden J, Galligan M, O'Toole A, McCarthy J, Doherty G.

BMJ Open Gastroenterol. 2018 Jan 11;5(1):e000174. doi: 10.1136/bmjgast-2017-000174. eCollection 2018.

3.

The Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of H. pylori infection in adult patients in Ireland.

Smith S, Boyle B, Brennan D, Buckley M, Crotty P, Doyle M, Farrell R, Hussey M, Kevans D, Malfertheiner P, Megraud F, Nugent S, O'Connor A, O'Morain C, Weston S, McNamara D.

Eur J Gastroenterol Hepatol. 2017 May;29(5):552-559. doi: 10.1097/MEG.0000000000000822.

PMID:
28350745
4.

Changes in Presentation of Celiac Disease in Ireland From the 1960s to 2015.

Dominguez Castro P, Harkin G, Hussey M, Christopher B, Kiat C, Liong Chin J, Trimble V, McNamara D, MacMathuna P, Egan B, Ryan B, Kevans D, Farrell R, Byrnes V, Mahmud N, McManus R.

Clin Gastroenterol Hepatol. 2017 Jun;15(6):864-871.e3. doi: 10.1016/j.cgh.2016.11.018. Epub 2016 Dec 31.

PMID:
28043932
5.

Treatment of Clostridium difficile infection: a national survey of clinician recommendations and the use of faecal microbiota transplantation.

Prior AR, Kevans D, McDowell L, Cudmore S, Fitzpatrick F.

J Hosp Infect. 2017 Apr;95(4):438-441. doi: 10.1016/j.jhin.2016.10.004. Epub 2016 Oct 14.

PMID:
28029471
6.

Association of host genome with intestinal microbial composition in a large healthy cohort.

Turpin W, Espin-Garcia O, Xu W, Silverberg MS, Kevans D, Smith MI, Guttman DS, Griffiths A, Panaccione R, Otley A, Xu L, Shestopaloff K, Moreno-Hagelsieb G; GEM Project Research Consortium, Paterson AD, Croitoru K.

Nat Genet. 2016 Nov;48(11):1413-1417. doi: 10.1038/ng.3693. Epub 2016 Oct 3.

PMID:
27694960
7.

Rates and Predictors of Endoscopic and Clinical Recurrence After Primary Ileocolic Resection for Crohn's Disease.

Fortinsky KJ, Kevans D, Qiang J, Xu W, Bellolio F, Steinhart H, Milgrom R, Greenberg G, Cohen Z, Macrae H, Stempak J, McLeod R, Silverberg MS.

Dig Dis Sci. 2017 Jan;62(1):188-196. doi: 10.1007/s10620-016-4351-7. Epub 2016 Oct 24.

PMID:
27778204
8.

Long-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis.

Hussey M, Mc Garrigle R, Kennedy U, Holleran G, Kevans D, Ryan B, Breslin N, Mahmud N, McNamara D.

Eur J Gastroenterol Hepatol. 2016 Feb;28(2):217-21. doi: 10.1097/MEG.0000000000000515.

PMID:
26587866
9.

Characterization of Intestinal Microbiota in Ulcerative Colitis Patients with and without Primary Sclerosing Cholangitis.

Kevans D, Tyler AD, Holm K, Jørgensen KK, Vatn MH, Karlsen TH, Kaplan GG, Eksteen B, Gevers D, Hov JR, Silverberg MS.

J Crohns Colitis. 2016 Mar;10(3):330-7. doi: 10.1093/ecco-jcc/jjv204. Epub 2015 Nov 2.

10.

IBD Genetic Risk Profile in Healthy First-Degree Relatives of Crohn's Disease Patients.

Kevans D, Silverberg MS, Borowski K, Griffiths A, Xu W, Onay V, Paterson AD, Knight J, Croitoru K; GEM Project.

J Crohns Colitis. 2016 Feb;10(2):209-15. doi: 10.1093/ecco-jcc/jjv197. Epub 2015 Oct 28.

11.

Determinants of intestinal permeability in healthy first-degree relatives of individuals with Crohn's disease.

Kevans D, Turpin W, Madsen K, Meddings J, Shestopaloff K, Xu W, Moreno-Hagelsieb G, Griffiths A, Silverberg MS, Paterson A, Croitoru K; GEM Project.

Inflamm Bowel Dis. 2015 Apr;21(4):879-87. doi: 10.1097/MIB.0000000000000323. Erratum in: Inflamm Bowel Dis. 2015 Jul.21(7):1673.

PMID:
25734694
12.

Genetics and innate and adaptive immunity in IBD.

Zanello G, Kevans D, Goethel A, Silverberg M, Tyler A, Croitoru K.

Nestle Nutr Inst Workshop Ser. 2014;79:41-55. doi: 10.1159/000360676. Epub 2014 Sep 5. Review.

PMID:
25227294
13.

Serological markers associated with disease behavior and response to anti-tumor necrosis factor therapy in ulcerative colitis.

Kevans D, Waterman M, Milgrom R, Xu W, Van Assche G, Silverberg M.

J Gastroenterol Hepatol. 2015 Jan;30(1):64-70. doi: 10.1111/jgh.12661.

PMID:
25041458
14.

Determinants of short- and long-term survival from colorectal cancer in very elderly patients.

Sheridan J, Walsh P, Kevans D, Cooney T, O'Hanlon S, Nolan B, White A, McDermott E, Sheahan K, O'Shea D, Hyland J, O'Donoghue D, O'Sullivan J, Mulcahy H, Doherty G.

J Geriatr Oncol. 2014 Oct 1;5(4):376-83. doi: 10.1016/j.jgo.2014.04.005. Epub 2014 May 18.

PMID:
24845215
15.
16.

Stage II colonic adenocarcinoma: a detailed study of pT4N0 with emphasis on peritoneal involvement and the role of tumour budding.

Canney AL, Kevans D, Wang LM, Hyland JM, Mulcahy HE, O'Donoghue DP, O'Sullivan J, Geraghty R, Sheahan K.

Histopathology. 2012 Sep;61(3):488-96. doi: 10.1111/j.1365-2559.2012.04250.x. Epub 2012 Mar 28.

PMID:
22463746
17.

Epithelial-mesenchymal transition (EMT) protein expression in a cohort of stage II colorectal cancer patients with characterized tumor budding and mismatch repair protein status.

Kevans D, Wang LM, Sheahan K, Hyland J, O'Donoghue D, Mulcahy H, O'Sullivan J.

Int J Surg Pathol. 2011 Dec;19(6):751-60. doi: 10.1177/1066896911414566. Epub 2011 Jul 26.

PMID:
21791486
18.

Mesalazine-induced bronchiolitis obliterans organizing pneumonia (BOOP) in a patient with ulcerative colitis and primary sclerosing cholangitis.

Kevans D, Greene J, Galvin L, Morgan R, Murray FE.

Inflamm Bowel Dis. 2011 Oct;17(10):E137-8. doi: 10.1002/ibd.21819. Epub 2011 Jul 14. No abstract available.

PMID:
21761513
19.

Clusterin and chemotherapy sensitivity under normoxic and graded hypoxic conditions in colorectal cancer.

Kevans D, Gorman S, Tosetto M, Sheahan K, O'Donoghue D, Mulcahy H, O'Sullivan J.

J Gastrointest Cancer. 2012 Jun;43(2):305-13. doi: 10.1007/s12029-011-9277-x.

PMID:
21487682
20.

Failed biliary access following needle knife fistulotomy: is repeat interval ERCP worthwhile?

Kevans D, Zeb F, Donnellan F, Courtney G, Aftab AR.

Scand J Gastroenterol. 2010 Oct;45(10):1238-41. doi: 10.3109/00365521.2010.495418.

PMID:
20553113
21.

Clinical and pathological factors associated with colorectal cancer at the upper extreme of life.

Doherty G, Walsh P, Sheridan J, Kevans D, Keegan D, Nolan B, White A, McDermott E, Sheahan K, O'Shea D, Hyland J, O'Donoghue D, O'Sullivan J, Mulcahy H.

J Am Geriatr Soc. 2010 Apr;58(4):794-5. doi: 10.1111/j.1532-5415.2010.02793.x. No abstract available.

PMID:
20398168
22.

NSAID-induced colopathy. A case series.

Aftab AR, Donnellan F, Zeb F, Kevans D, Cullen G, Courtney G.

J Gastrointestin Liver Dis. 2010 Mar;19(1):89-91.

23.

Duodenal impaction/perforation of a biliary stent--a rare complication in the management of choledocholithiasis.

Zeb F, Kevans D, Muir K, Courtney G, Tadros E, Aftab A.

J Gastrointestin Liver Dis. 2009 Sep;18(3):391-2. No abstract available.

PMID:
19795045
24.

Gallbladder wall variceal haemorrhage with associated rupture: a rare cause of mortality in the cirrhotic patient.

Kevans D, MacNicholas R, Norris S.

Eur J Gastroenterol Hepatol. 2009 Aug;21(8):955-7.

PMID:
19598330
25.

Localization of nuclear cathepsin L and its association with disease progression and poor outcome in colorectal cancer.

Sullivan S, Tosetto M, Kevans D, Coss A, Wang L, O'Donoghue D, Hyland J, Sheahan K, Mulcahy H, O'Sullivan J.

Int J Cancer. 2009 Jul 1;125(1):54-61. doi: 10.1002/ijc.24275.

26.

High clusterin expression correlates with a poor outcome in stage II colorectal cancers.

Kevans D, Foley J, Tenniswood M, Sheahan K, Hyland J, O'Donoghue D, Mulcahy H, O'Sullivan J.

Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):393-9. doi: 10.1158/1055-9965.EPI-08-0302. Epub 2009 Jan 20.

27.

Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer.

Wang LM, Kevans D, Mulcahy H, O'Sullivan J, Fennelly D, Hyland J, O'Donoghue D, Sheahan K.

Am J Surg Pathol. 2009 Jan;33(1):134-41. doi: 10.1097/PAS.0b013e318184cd55.

PMID:
18971777
28.

Reversible acute reactive arthritis secondary to iatrogenic blind loop syndrome.

Kevans D, Smyth C, O'Brien C, Broe P, Patchett S.

J Gastrointestin Liver Dis. 2007 Sep;16(3):349. No abstract available.

29.

Haematological support during peg-interferon therapy for HCV-infected haemophiliacs improves virological outcomes.

Kevans D, Farrell G, Hopkins S, Mahmud N, White B, Norris S, Bergin C.

Haemophilia. 2007 Sep;13(5):593-8.

PMID:
17880449
30.

Infliximab therapy in Crohn's disease: a pragmatic approach?

Kevans D, Keegan D, Mulcahy HE, O'Donoghue DP.

Aliment Pharmacol Ther. 2006 Jul 15;24(2):351-9.

Supplemental Content

Loading ...
Support Center